PharMerica CORP
Consumer Discretionary · Retail-Drug Stores and Proprietary Stores · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $524.5M | $511.6M | $1.89B | $1.76B | $498.9M | $535.1M |
| Operating income | $7.9M | $16.8M | $30.4M | $55.8M | $12.0M | $6.7M |
| Net income | $4.1M | $9.6M | $6.8M | $18.9M | $5.6M | $3.3M |
| Total assets | $1.30B | $1.15B | $1.07B | $900.8M | $885.7M | $834.0M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $544.2M | $519.4M | $478.1M | $462.5M | $442.6M | $413.8M |
| EPS (diluted) | $0.13 | $0.31 | $0.22 | $0.63 | $0.19 | $0.11 |
| Shares out. | 30.5M | 30.2M | 29.7M | 29.5M | 29.4M | 29.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- 1.5%
- Net margin
- 0.8%
- Return on equity
- 0.8%
- Return on assets
- 0.3%
- Return on capital (ROCE)
- 0.7%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $17.83
- Revenue growth (YoY)
- 2.5%
- Net income growth (YoY)
- −57.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Accruals / assets
- −2.1%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 7, 2017
- Results of operationsNov 9, 2017
- Shareholder vote · Other material eventNov 9, 2017
- Other material eventOct 27, 2017
- Other material eventAug 28, 2017
- Entered a material agreementAug 3, 2017
- Results of operationsAug 2, 2017
- Other material eventAug 2, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 13, 2018
- SC 13G/ASCHEDULE 13G/AFeb 9, 2018
- 15-12BDec 18, 2017
- 4FORM 4 SUBMISSIONDec 11, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
- 4FORM 4 SUBMISSIONDec 8, 2017
Corporate family
Spun off from AmerisourceBergenCOR · Mar 26, 2007
From the spin-off filings we track. Follow a company to walk its own history.